摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Nα-benzoyl-L-phenylalanine-L-valine-L-arginine-p-nitroanilide hydrochloride | 38789-84-3

中文名称
——
中文别名
——
英文名称
Nα-benzoyl-L-phenylalanine-L-valine-L-arginine-p-nitroanilide hydrochloride
英文别名
N-α-benzoyl-Phe-Val-Arg-p-NA;n-benzoyl-L-phenylalanyl-L-valyl-L-arginine-p-nitroanilide.HCl;N-Benzoyl-Phe-Val-Arg-p-nitroanilide hydrochloride;N-[(2S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide;hydrochloride
Nα-benzoyl-L-phenylalanine-L-valine-L-arginine-p-nitroanilide hydrochloride化学式
CAS
38789-84-3
化学式
C33H40N8O6*ClH
mdl
——
分子量
681.192
InChiKey
PYVSMZDQQUZGPF-JAQKLANPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.89
  • 重原子数:
    48
  • 可旋转键数:
    15
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    227
  • 氢给体数:
    7
  • 氢受体数:
    7

文献信息

  • Process for determining inhibitor-enzyme complexes
    申请人:CORNELL RESEARCH FOUNDATION, INC.
    公开号:EP0048989A2
    公开(公告)日:1982-04-07
    This invention relates to methods for detecting, identifying and quantifying enzymes, for example, human proteolytic enzymes. The method broadly comprises forming an immobilized or insoluble complex comprising enzyme, enzyme inhibitor and enzyme inhibitor-antibody reactive site and then detecting and identifying, preferably quantitatively, one or more enzymes bound to the complex. In a preferrend embodiment, a matrix, e.g. solid or semisolid surface or permeable matrix, has affixed thereto enzyme inhibitor-antibody or an immunologically active (inhibitor binding) fragment of such an antibody. This insoluble enzyme inhibitor interacting matrix is then contacted with biological fluid, e.g. body fluid, to bind one or more predetermined enzyme inhibitor-enzyme complexes, if present in the biological fluid. The bound enzyme is then detected, identified and preferably quantified.
    本发明涉及检测、鉴定和定量酶的方法,例如人类蛋白解酶。该方法大致包括形成由酶、酶抑制剂和酶抑制剂-抗体反应位点组成的固定化或不溶性复合物,然后检测和鉴定(最好是定量检测和鉴定)与该复合物结合的一种或多种酶。 在一个优选的实施方案中,基质(例如固体或半固体表面或可渗透基质)上贴有酶抑制剂-抗体或这种抗体的免疫活性(抑制剂结合)片段。然后将这种不溶性酶抑制剂相互作用基质与生物液体(如体液)接触,以结合生物液体中存在的一种或多种预定的酶抑制剂-酶复合物。然后对结合的酶进行检测、鉴定和优选定量。
  • Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut
    申请人:Axcess Limited
    公开号:EP2873420A1
    公开(公告)日:2015-05-20
    The present invention relates to a compound for use in a method of treatment of the human or animal body by therapy, in which method (i) the human or animal body is treated by administering one or more therapeutic peptides, and (ii) said compound is administered to inhibit degradation of said one or more peptides by one or more gut proteases, wherein the compound is a bile acid or a biguanide, or a pharmaceutically acceptable salt of a bile acid or a biguanide, wherein said bile acid is chosen from chenodeoxycholic acid, ursodeoxycholic acid, glycochenodeoxycholic acid and glycodeoxycholic acid.
    本发明涉及一种用于人或动物机体治疗方法的化合物,在该方法中,(i)通过施用一种或多种治疗肽对人或动物机体进行治疗,(ii)施用所述化合物以抑制一种或多种肠道蛋白酶对所述一种或多种肽的降解、 其中所述化合物是胆汁酸或双胍,或胆汁酸或双胍的药学上可接受的盐,其中所述胆汁酸选自辰去氧胆酸熊去氧胆酸、甘辰去氧胆酸和甘去氧胆酸
  • BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT
    申请人:Axcess Limited
    公开号:EP2361091B1
    公开(公告)日:2015-01-21
  • Inhibitors Of Neurotrypsin
    申请人:Sonderegger Peter
    公开号:US20090170950A1
    公开(公告)日:2009-07-02
    The invention relates to a method for determining whether a compound is a neurotrypsin inhibitor, characterized in that the compound is incubated together with neurotrypsin, a variant thereof or a fragment comprising the protease domain and with a protein or peptide comprising agrin, a variant thereof or a fragment comprising the α- or the β-cleavage site of agrin, in an aqueous buffer solution, and the amount of cleavage of agrin is measured. Additionally, the invention relates to inhibitors of neurotrypsin found by this method, in particular to compounds of formula wherein Hal 1 and Hal 2 are fluorine, chlorine or bromine, and the use of such inhibitors for the treatment and/or prophylaxis of diseases caused by deficiency of synapses, for example skeletal muscle atrophy, schizophrenia, and cognitive disturbance.
  • US4118481A
    申请人:——
    公开号:US4118481A
    公开(公告)日:1978-10-03
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸